Soliciting Strategies for Developing Cell-Based Reference Materials to Advance Mesenchymal Stromal Cell Research and Clinical Translation

Viswanathan, Sowmya; Keating, Armand; Deans, Robert; Hematti, Peiman; Prockop, Darwin J.; Stroncek, David F.; Stacey, Glyn; Weiss, Dan; Mason, Christopher; Rao, Mahendra S.

doi:10.1089/scd.2013.0591

Cited by 109 publications

(72 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…As a result, standardization of the cells has been extremely difficult and the data presented in different publications are difficult to compare. Hence large banks of reference cells are needed to advance the MSC research (26).…”

mentioning

confidence: 99%

MSCs derived from iPSCs with a modified protocol are tumor-tropic but have much less potential to promote tumors than bone marrow MSCs

Zhao¹,

Gregory²,

Lee³

et al. 2014

Proc. Natl. Acad. Sci. U.S.A.

136

135

View full text Add to dashboard Cite

Mesenchymal stem or stromal cells (MSCs) have many potential therapeutic applications including therapies for cancers and tissue damages caused by cancers or radical cancer treatments. However, tissue-derived MSCs such as bone marrow MSCs (BM-MSCs) may promote cancer progression and have considerable donor variations and limited expandability. These issues hinder the potential applications of MSCs, especially those in cancer patients. To circumvent these issues, we derived MSCs from transgene-free human induced pluripotent stem cells (iPSCs) efficiently with a modified protocol that eliminated the need of flow cytometric sorting. Our iPSC-derived MSCs were readily expandable, but still underwent senescence after prolonged culture and did not form teratomas. These iPSC-derived MSCs homed to cancers with efficiencies similar to BM-MSCs but were much less prone than BM-MSCs to promote the epithelial-mesenchymal transition, invasion, stemness, and growth of cancer cells. The observations were probably explained by the much lower expression of receptors for interleukin-1 and TGFβ, downstream protumor factors, and hyaluronan and its cofactor TSG6, which all contribute to the protumor effects of BM-MSCs. The data suggest that iPSC-derived MSCs prepared with the modified protocol are a safer and better alternative to BM-MSCs for therapeutic applications in cancer patients. The protocol is scalable and can be used to prepare the large number of cells required for "off-the-shelf" therapies and bioengineering applications.

show abstract

mentioning

confidence: 99%

MSCs derived from iPSCs with a modified protocol are tumor-tropic but have much less potential to promote tumors than bone marrow MSCs

Zhao¹,

Gregory²,

Lee³

et al. 2014

Proc. Natl. Acad. Sci. U.S.A.

136

135

View full text Add to dashboard Cite

show abstract

“…The information in Tables 1 and 2 was based on comparable tables in previous conference reports and was updated with contributions from each author based on discussions that occurred at the conference. [31,40,41]). He demonstrated that in a corneal injury model, the efficacy of MSCs correlated with the transcription levels of the antiinflammatory molecule, tumor necrosis factor-inducible gene 6 protein (TSG6) (42).…”

Section: Methodsmentioning

confidence: 99%

“…He demonstrated that in a corneal injury model, the efficacy of MSCs correlated with the transcription levels of the antiinflammatory molecule, tumor necrosis factor-inducible gene 6 protein (TSG6) (42). His work highlighted the importance of finding appropriate markers of efficacy against inflammation that can be easily assayed and that appear to be distinct from the cell surface markers and other criteria that are currently used to define MSCs (40). The considerable variation documented among some of the characteristics of MSCs derived from different donors highlighted one of the dilemmas facing the clinical translation of this cell population and raised concerns among some about the need for reproducible potency assays.…”

Section: Methodsmentioning

confidence: 99%

An Official American Thoracic Society Workshop Report: Stem Cells and Cell Therapies in Lung Biology and Diseases

Weiss¹,

Chambers²,

Giangreco³

et al. 2015

Annals ATS

Self Cite

View full text Add to dashboard Cite

The University of Vermont College of Medicine and the Vermont Lung Center, in collaboration with the NHLBI, Alpha-1 Foundation, American Thoracic Society, European Respiratory Society, International Society for Cell Therapy, and the Pulmonary Fibrosis Foundation, convened a workshop, "Stem Cells and Cell Therapies in Lung Biology and Lung Diseases," held July 29 to August 1, 2013 at the University of Vermont. The conference objectives were to review the current understanding of the role of stem and progenitor cells in lung repair after injury and to review the current status of cell therapy and ex vivo bioengineering approaches for lung diseases. These are all rapidly expanding areas of study that both provide further insight into and challenge traditional views of mechanisms of lung repair after injury and pathogenesis of several lung diseases. The goals of the conference were to summarize the current state of the field, discuss and debate current controversies, and identify future research directions and opportunities for both basic and translational research in cell-based therapies for lung diseases. This conference was a follow-up to four previous biennial conferences held at the University

show abstract

“…Potential ways of defining bioprocessisng metrics could be carried out and even the adoption of reference MSC lines has been suggested as a calibration tool [49,50]. In addition, knowledge on the impact of manufacturing at different sites on MSC product quality is still rather limited and should be explored as this model of production would rely on such production and distribution strategies.…”

Section: On Quality Control and Product Comparabilitymentioning

confidence: 99%

Bioprocess engineering strategies for autologous human MSC-based therapies: one size does not fit all

Papantoniou¹,

Lambrechts²,

Aerts³

2017

Cell Gene Therapy Insights

View full text Add to dashboard Cite

Soliciting Strategies for Developing Cell-Based Reference Materials to Advance Mesenchymal Stromal Cell Research and Clinical Translation

Cited by 109 publications

References 33 publications

MSCs derived from iPSCs with a modified protocol are tumor-tropic but have much less potential to promote tumors than bone marrow MSCs

MSCs derived from iPSCs with a modified protocol are tumor-tropic but have much less potential to promote tumors than bone marrow MSCs

An Official American Thoracic Society Workshop Report: Stem Cells and Cell Therapies in Lung Biology and Diseases

Bioprocess engineering strategies for autologous human MSC-based therapies: one size does not fit all

Contact Info

Product

Resources

About